Search results
Results From The WOW.Com Content Network
Employer. Novo Nordisk (since 1994) Lars Fruergaard Jørgensen (born 29 November 1966) [ 1] is a Danish businessman, the Chief Executive of Novo Nordisk since January 2017 and Chairman of the European Federation of Pharmaceutical Industries and Associations . He was named as the Financial Times Person of the Year in December 2023.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd [ 3] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.
Profits from Novo Nordisk generate returns for the Novo Nordisk Foundation, which holds the controlling stake in Novo Nordisk. The profits results in increased Danish tax revenues and employment. Novo Nordisk added 3,500 jobs in Denmark in 2022, bringing the total in the country to 21,000 employees, out of 59,000 worldwide. [80]
The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent, a ...
The Novo Nordisk Foundation didn't return Yahoo Finance's request to be interviewed for this story. Allie Garfinkle is a Senior Tech Reporter at Yahoo Finance. Follow her on X, formerly Twitter ...
Novo Nordisk announced the largest private life science investment in state history Monday, committing $4.1 billion to expand its Johnston County facility, a project the Danish drugmaker says will ...
Repaglinide. Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [ 1] The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the ...
Novo Nordisk is a leading company in both weight loss and diabetes care. If Victoza and Saxenda can give the business a boost, that will be great news for investors.